Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises M42 on its acquisition of Diaverum from Bridgepoint
Mandate

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

May 22, 2023 M&A

Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.

M42 is a global tech-enabled healthcare leader operating at the forefront of medical development. Diaverum is currently the world’s third-largest provider of dialysis services, operating across 23 countries, with 440 clinics and over 13,000 employees. The acquisition of Diaverum significantly expands M42’s global geographic footprint, enabling it to introduce relevant healthcare services and healthtech solutions in new markets while further enhancing its renal care offering in the GCC. The transaction, which is subject to customary regulatory approvals, is expected to close later in 2023.

Vinges team consisted of Matthias Pannier, Stina Bengtsson, Christoffer Nordin, Josefin Lanker och Josef Groow.

 

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB.
February 22, 2026

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

 Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026

Vinge advises Zengun in connection with its issuance of bonds in an amount of SEK 750 million and its early redemption of outstanding bonds

 Vinge has advised Zengun Group AB (publ) in connection with its issuance of senior secured bonds in an amount of SEK 750 million (within a framework of SEK 1,500 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
February 20, 2026